Allergan PLC. (AGN) Shares Bought by Virginia Retirement Systems ET AL
Virginia Retirement Systems ET AL boosted its position in shares of Allergan PLC. (NYSE:AGN) by 139.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 113,514 shares of the company’s stock after buying an additional 66,200 shares during the period. Virginia Retirement Systems ET AL’s holdings in Allergan PLC. were worth $26,143,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Jackson Square Partners LLC raised its stake in Allergan PLC. by 5.7% in the second quarter. Jackson Square Partners LLC now owns 3,840,160 shares of the company’s stock worth $1,004,656,000 after buying an additional 205,701 shares in the last quarter. General Electric Co. raised its stake in Allergan PLC. by 13.7% in the second quarter. General Electric Co. now owns 2,676,658 shares of the company’s stock worth $618,549,000 after buying an additional 322,108 shares in the last quarter. Veritas Asset Management LLP purchased a new stake in Allergan PLC. during the second quarter worth approximately $492,177,000. Thornburg Investment Management Inc. raised its stake in Allergan PLC. by 133.2% in the second quarter. Thornburg Investment Management Inc. now owns 1,717,844 shares of the company’s stock worth $396,977,000 after buying an additional 981,355 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its stake in Allergan PLC. by 12.6% in the second quarter. Adage Capital Partners GP L.L.C. now owns 1,402,893 shares of the company’s stock worth $324,195,000 after buying an additional 156,959 shares in the last quarter. Institutional investors own 86.72% of the company’s stock.
Shares of Allergan PLC. (NYSE:AGN) opened at 216.24 on Friday. The company has a market cap of $81.11 billion, a PE ratio of 6.06 and a beta of 1.02. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $301.98. The firm’s 50-day moving average is $200.06 and its 200-day moving average is $225.49.
Allergan PLC. (NYSE:AGN) last posted its earnings results on Wednesday, November 2nd. The company reported $3.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.65 by $0.33. Allergan PLC. had a net margin of 93.74% and a return on equity of 7.26%. The company earned $3.62 billion during the quarter, compared to analysts’ expectations of $3.73 billion. During the same quarter last year, the firm earned $3.48 EPS. Allergan PLC.’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, equities analysts forecast that Allergan PLC. will post $13.39 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 28th. Shareholders of record on Tuesday, February 28th will be paid a $0.70 dividend. This represents a $2.80 annualized dividend and a yield of 1.29%. The ex-dividend date is Friday, February 24th. This is a positive change from Allergan PLC.’s previous quarterly dividend of $0.05.
AGN has been the topic of a number of research analyst reports. Bank of America Corporation set a $294.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Tuesday, September 20th. Goldman Sachs Group, Inc. (The) downgraded shares of Allergan PLC. from a “conviction-buy” rating to a “buy” rating in a research report on Wednesday, December 21st. Deutsche Bank AG reissued a “buy” rating and set a $247.00 price objective (up from $245.00) on shares of Allergan PLC. in a research report on Friday, December 23rd. J P Morgan Chase & Co set a $300.00 price objective on shares of Allergan PLC. and gave the company a “buy” rating in a research report on Monday, December 5th. Finally, RBC Capital Markets reissued an “outperform” rating and set a $279.00 price objective (down from $300.00) on shares of Allergan PLC. in a research report on Thursday, November 3rd. Eight research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $273.10.
In other Allergan PLC. news, CEO Brent L. Saunders purchased 5,250 shares of the company’s stock in a transaction dated Monday, November 21st. The shares were acquired at an average price of $189.13 per share, for a total transaction of $992,932.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Maria Teresa Hilado purchased 1,422 shares of the company’s stock in a transaction dated Friday, November 11th. The shares were acquired at an average price of $210.64 per share, for a total transaction of $299,530.08. Following the purchase, the chief financial officer now directly owns 12,659 shares of the company’s stock, valued at approximately $2,666,491.76. The disclosure for this purchase can be found here. 0.27% of the stock is owned by company insiders.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.